Effects of Colchicine and Empagliflozin in Myocardial Dysfunctio

Phase 3

• Conditions: Condition 1: Heart failure. Condition 2: ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction.; Heart failure; ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

• Registration Number: IRCT20111206008307N39
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

Heart Failure with Reduced Ejection Fraction
Aged 18 to 80 years
Consented patients

Exclusion Criteria

Pregnancy
Lactation
Liver failure
Kidney failure
Contraindications of colchicine or empagliflozin
Systolic blood pressure less than 100 or more than 180 mm Hg
Symptomatic hypotension
Autoinflammatory diseases
Malignancy
Diabetes mellitus

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Laboratory test.;New York Heart Association (NYHA) Functional Classification. Timepoint: At baseline and 1, and 3 months after intervention. Method of measurement: Assessment by one cardiologist.